PDS Biotechnology Corporation (PDSB) has a consensus analyst rating of Buy, based on 7 analysts covering the stock. Of those, 6 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for PDSB is $9.00, representing a +749.1% upside from the current price of $1.06. Price targets range from a low of $9.00 to a high of $9.00.
